8-K: NeOnc Executives Buy Shares After Positive Trial Data

NeOnc Technologies Holdings, Inc. reports significant open-market stock purchases by its CEO and Chief Medical Officer following positive Phase 2a results for its NEO100 therapy.

Summary

• NeOnc Technologies Holdings, Inc. announced that its Executive Chairman, President, and CEO, Amir F. Heshmatpour, purchased an additional 35,000 shares of common stock on September 15, 2026, for approximately $115,400.
• This purchase follows positive topline Phase 2a results for intranasal NEO100 announced on August 12, 2026.
• Since the positive results, CEO Heshmatpour has bought a total of 111,000 shares for approximately $418,700.
• Chief Medical Officer Thomas C. Chen also purchased 49,016 shares for approximately $210,000.
• In total, these two executives have acquired 160,016 shares for approximately $629,000 in open-market transactions.
• The Phase 2a study for NEO100 met its primary endpoint, showing a six-month progression-free survival of 48.9% compared to a benchmark of 20% (p = 0.0047), with a median overall survival of 26.09 months.
• The company's other program, NEO212, has completed Phase 1 and established a recommended Phase 2 dose.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, with significant insider buying following promising clinical trial results, indicating strong management confidence.

Positives

• Significant insider buying by senior leadership, totaling approximately $629,000, demonstrates strong confidence in the company's prospects.
• Positive topline Phase 2a results for NEO100, meeting its primary endpoint with a 48.9% six-month progression-free survival rate, significantly exceeding the 20% benchmark.
• CEO Amir F. Heshmatpour has personally invested over $1.5 million in NeOnc shares over the past year, reinforcing his commitment.
• NEO100 achieved a median overall survival of 26.09 months in the Phase 2a study.
• The NEO212 program has successfully completed Phase 1 and identified a recommended Phase 2 dose.
• The company holds patent protections for its NEO drug development platform extending to 2038.
• NEO100 and NEO212 have FDA Fast-Track and Investigational New Drug (IND) status.

Negatives

• The Phase 2a study for NEO100 was a single-arm, open-label study with 24 patients, not reaching its planned enrollment of 28, and was not powered as a confirmatory trial.
• Results were not compared against a randomized control arm, and comparisons to historical data are inherently limited.
• The primary efficacy analysis presented used RANO 2.0 criteria, and results differ under the response criteria and estimation method specified in the study protocol.
• Early-phase results may not replicate in larger, controlled studies.
• Safety and tolerability findings from a small, open-label study may not predict the safety profile in larger or longer-duration studies.

Risks

• The Phase 2a study was a single-arm, open-label study of 24 patients that did not reach its planned enrollment of 28 patients and was not powered as a confirmatory trial.
• Results were not compared against a randomized control arm, and comparisons to historical data are inherently limited by differences in patient population, era, and assessment criteria.
• The primary efficacy analysis presented reflects RANO 2.0 criteria and Kaplan-Meier estimation, and results differ under the response criteria and estimation method specified in the study protocol.
• Early-phase results frequently fail to replicate in larger, controlled studies.
• Safety and tolerability findings in a 24-patient, open-label study may not predict the safety profile observed in larger or longer-duration studies, and additional adverse events may emerge with broader exposure.
• The FDA may not agree with the Company's proposed registrational path, endpoints, or analytical methods.
• Additional pre-specified analyses remain ongoing.

Future Outlook

The company plans to engage with the FDA regarding its proposed registrational path, endpoints, and analytical methods for NEO100. Future clinical trials are planned, and the company continues its development strategy for its NEO platform.

Management Comments

• "The strength of our Phase 2a results reinforces my conviction in NeOnc's mission and the potential of our NEO platform."
• "With my most recent open-market purchases, I have now invested more than $1.5 million of my personal funds in NeOnc shares over the past year. This is a personal investment in our mission, our patients and the long-term value we are working to build alongside our shareholders."

Industry Context

StockSavvy.ai notes that significant insider buying, especially following positive clinical trial data, is a strong signal in the biopharmaceutical sector. This activity by NeOnc's leadership suggests high conviction in the therapeutic potential of NEO100 and the company's overall strategy, particularly in the competitive CNS cancer market.

Comparison to Industry Standards

• The Phase 2a study's six-month progression-free survival of 48.9% significantly surpasses the pre-specified benchmark of 20% for standard of care in malignant gliomas.
• The median overall survival of 26.09 months for NEO100 in the Phase 2a study is a notable outcome for a Phase 2 trial in this indication.
• The company's approach of developing novel therapies for CNS cancers, addressing the blood-brain barrier challenge, aligns with ongoing industry efforts to find more effective treatments for these difficult-to-treat diseases.

Stakeholder Impact

• Shareholders: Increased confidence due to positive trial data and significant insider investment may lead to positive stock performance.
• Patients: Potential for a more effective treatment option for CNS cancers with the advancement of NEO100.
• Employees: Continued development and potential success of the company's therapies can lead to job security and growth opportunities.

Next Steps

• Engage with the FDA regarding the proposed registrational path, endpoints, and analytical methods for NEO100.
• Continue development of the NEO212 program, which has established a recommended Phase 2 dose.
• Conduct additional pre-specified analyses for the NEO100 Phase 2a study.

Key Dates

Recommendation

The positive Phase 2a results and significant insider buying are strong positives. However, the limitations of the Phase 2a study (single-arm, not reaching enrollment targets, protocol deviations in analysis) and the need for FDA agreement on the registrational path introduce considerable uncertainty. The recent capital raise also dilutes existing shareholders. Therefore, a 'hold' recommendation is appropriate pending further clarity on the regulatory path and confirmatory trial results.

Keywords

NEO100, biopharmaceutical, CNS cancer, clinical trial, insider buying, Phase 2a, progression-free survival, CEO investment